	US 11,926,664 B2
	Methods and pharmaceutical compositions for modulating monocytopoiesis
Lionel Poulin, Lille (FR); Corentin Lasseaux, Lille (FR); and Mathias Chamaillard, Lille (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); INSTITUT PASTEUR DE LILLE, Lille (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITÉ DE LILLE, Lille (FR)
Appl. No. 16/633,900
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); INSTITUT PASTEUR DE LILLE, Lille (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITÉ DE LILLE, Lille (FR)
PCT Filed Jul. 24, 2018, PCT No. PCT/EP2018/069973 § 371(c)(1), (2) Date Jan. 24, 2020, PCT Pub. No. WO2019/020593, PCT Pub. Date Jan. 31, 2019.
Claims priority of application No. 17305990 (EP), filed on Jul. 25, 2017.
Prior Publication US 2020/0216530 A1, Jul. 9, 2020
Int. Cl. C07K 16/24 (2006.01); A61K 38/21 (2006.01)

CPC C07K 16/249 (2013.01) [A61K 38/212 (2013.01); C07K 2317/76 (2013.01)]

7 Claims

1. A method of reducing monocytopoiesis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-IFNα neutralizing antibody, wherein the patient has a cancer, and the an anti-IFNα neutralizing antibody reduces monocytopoiesis in the patient.